UBS Trims TIGERMED (03347.HK) TP to $173.82, Rated Buy
UBS Trims TIGERMED (03347.HK) TP to $173.82, Rated Buy
TIGERMED (03347.HK) will likely benefit from the more stringent new regulations on anti-tumor drugs introduced by China National Medical Products Administration (NMPA), while its overseas business is believed to be able to serve as a new growth driver, reported UBS. The broker kept the Buy rating for TIGERMED, while cutting its target price from $246.76 to $173.82.
UBS added that the strong order backlog of TIGERMED will ensure the earnings growth of the company in short to medium term.
The company has more than 140 overseas clinical trial projects and over 30 global multi-center clinical trials. With more Chinese innovative drug R&D companies poised to venture into the overseas market, the overseas operation of TIGERMED is expected to enjoy ample room of growth, the broker remarked.
據瑞銀報道，泰格醫藥(03347.HK)可能會受益於中國國家醫藥品監督管理局(NMPA)出臺的更嚴格的抗腫瘤藥物新規，而其海外業務被認為能夠成為新的增長動力。該經紀商維持對泰格醫藥的買入評級，同時將其目標價從246.76美元下調至173.82美元。
瑞銀補充稱，泰格醫藥的強勁積壓訂單將確保公司中短期的盈利增長。
該公司擁有140多個海外臨牀試驗項目和30多個全球多中心臨牀試驗。這位經紀人表示，隨着更多的中國創新藥物研發公司準備進軍海外市場，泰格醫藥的海外業務預計將有很大的增長空間。
